Power3 Medical Files Patents for Protein Biomarkers

Biomarkers In Human Blood Serum Can Identify Neurodegenerative Disease

THE WOODLANDS, Texas -- Power3 Medical Products, Inc. (OTCBB: PWRM) has filed a U.S. Utility Patent application for 47 protein biomarkers of neurodegenerative disease in human blood serum. Power3 Medical, located in The Woodlands, is a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases,

Power3 Medical has determined the blood serum concentrations of these forty-seven biomarkers in samples from more than 750 neurodegenerative disease patients and normal control subjects. The results have shown that this group of biomarkers is useful in the differential diagnosis of Alzheimer’s disease (AD) from normal control individuals, patients with non-Alzheimer’s dementias, and patients with Parkinson’s disease or ALS (Lou Gehrig’s disease). Eighteen million people worldwide have AD; because the early signs of Alzheimer’s disease are often hard to distinguish from normal signs of aging, many patients are not diagnosed until the neuronal damage caused by this disease is extensive.

“When Power3 identifies a new biomarker, we fully characterize it so that we know the precise molecules which make up the blood serum protein,” states Dr. Ira L. Goldknopf, Power3’s Director of Proteomics and Senior Inventor. “One of the most critical issues in the diagnosis of Alzheimer’s disease is the ability to distinguish AD from other forms of dementia and other neurological and vascular disorders. Power3’s group of protein biomarkers in blood serum can be employed for such a differential diagnosis, which will accelerate both the diagnosis and the delivery of treatment.”

“Power3’s identification of these forty-seven biomarkers, based on our unique, proprietary proteomic discovery platform, is critical to the value of our intellectual property. These biomarkers are essential discoveries that will be used in the development of high-throughput commercial diagnostic tests, monitoring the progress of patients during treatment or clinical trials, and in identifying novel drug targets,” comments Steven Rash, Power3’s Chief Executive Officer. “Early and accurate diagnostics for Alzheimer’s disease is a critical unmet need for patients, physicians, and pharmaceutical companies. Currently, the only definitive diagnosis of AD is performed by examining the disease neuropathological features of the brain cells at autopsy.”

About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro™, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.